{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:01:44Z","timestamp":1793156504802,"version":"4.5.0"},"reference-count":275,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Metabolism"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cmet.2026.02.018","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:55:22Z","timestamp":1774277722000},"page":"1054-1074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["The many pathways driving liver inflammation in MASH"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4235-2579","authenticated-orcid":false,"given":"Herbert","family":"Tilg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timon E.","family":"Adolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmet.2026.02.018_bib1","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"Israelsen","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2026.02.018_bib2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.2025.19615","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults: a review","volume":"335","author":"Tilg","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.cmet.2026.02.018_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-025-00599-1","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults","volume":"11","author":"Huang","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.cmet.2026.02.018_bib4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib6","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2026.02.018_bib7","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1093\/eurheartj\/ehaf314","article-title":"Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement","volume":"46","author":"Romeo","year":"2025","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cmet.2026.02.018_bib8","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.cmet.2026.02.018_bib9","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib10","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jhep.2024.11.028","article-title":"Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease","volume":"82","author":"Arab","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib11","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cgh.2025.02.017","article-title":"An expert consensus Delphi panel in metabolic dysfunction- and alcohol-associated liver disease: opportunities and challenges in clinical practice","volume":"24","author":"Diaz","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib12","doi-asserted-by":"crossref","first-page":"101185","DOI":"10.1016\/j.jhepr.2024.101185","article-title":"Lipid metabolism in MASLD and MASH: From mechanism to the clinic. JHEP Rep 6","volume":"6","author":"Carli","year":"2024","journal-title":"JHEP Rep."},{"key":"10.1016\/j.cmet.2026.02.018_bib13","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1053\/j.gastro.2012.09.008","article-title":"Sterile inflammation in the liver","volume":"143","author":"Kubes","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmet.2026.02.018_bib14","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/s42255-021-00501-9","article-title":"Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity","volume":"3","author":"Tilg","year":"2021","journal-title":"Nat. Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib15","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cmet.2024.05.003","article-title":"Metabolic reprogramming in liver fibrosis","volume":"36","author":"Horn","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib16","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2010.12.017","article-title":"C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients","volume":"55","author":"Zimmermann","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib17","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2011.10.005","article-title":"Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans","volume":"56","author":"Pihlajam\u00e4ki","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib18","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1136\/gutjnl-2023-330815","article-title":"Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease","volume":"73","author":"Armandi","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.cmet.2026.02.018_bib19","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmet.2026.02.018_bib20","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib21","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2024.11.049","article-title":"A new generation of non-invasive tests of liver fibrosis with improved accuracy in MASLD","volume":"82","author":"Cal\u00e8s","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jhep.2018.09.024","article-title":"Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib","volume":"70","author":"Jayakumar","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib23","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib24","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in atherosclerosis: from pathophysiology to practice","volume":"54","author":"Libby","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cmet.2026.02.018_bib25","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib26","doi-asserted-by":"crossref","first-page":"119053","DOI":"10.1016\/j.atherosclerosis.2024.119053","article-title":"Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"400","author":"Iturbe-Rey","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cmet.2026.02.018_bib27","doi-asserted-by":"crossref","first-page":"ITC1","DOI":"10.7326\/ANNALS-24-02933","article-title":"Metabolic dysfunction-associated steatotic liver disease","volume":"178","author":"Ali","year":"2025","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib28","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.cmet.2024.01.011","article-title":"DGAT2 inhibition blocks SREBP-1 cleavage and improves hepatic steatosis by increasing phosphatidylethanolamine in the ER","volume":"36","author":"Rong","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/hep.20783","article-title":"Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice","volume":"42","author":"Yu","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib31","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(20)30186-2","article-title":"Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial","volume":"5","author":"Loomba","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib32","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(25)00979-1","article-title":"Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"406","author":"Loomba","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2026.02.018_bib33","doi-asserted-by":"crossref","first-page":"22678","DOI":"10.1074\/jbc.M704213200","article-title":"Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance","volume":"282","author":"Choi","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cmet.2026.02.018_bib34","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib35","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","article-title":"Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia","volume":"34","author":"Morrow","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib36","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-025-09297-0","article-title":"ACLY inhibition promotes tumour immunity and suppresses liver cancer","volume":"645","author":"Gautam","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib37","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.cmet.2022.10.007","article-title":"MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity","volume":"34","author":"Cheng","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib38","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib39","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.cell.2022.04.004","article-title":"Atherosclerosis: Recent developments","volume":"185","author":"Bj\u00f6rkegren","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2026.02.018_bib40","doi-asserted-by":"crossref","first-page":"e0434","DOI":"10.1097\/HC9.0000000000000434","article-title":"An overview of the cholesterol metabolism and its proinflammatory role in the development of MASLD","volume":"8","author":"Zhang","year":"2024","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.cmet.2026.02.018_bib41","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cmet.2006.07.006","article-title":"Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis","volume":"4","author":"Mar\u00ed","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib42","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cmet.2012.04.004","article-title":"Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease","volume":"15","author":"Min","year":"2012","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib43","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","article-title":"Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.cmet.2026.02.018_bib44","doi-asserted-by":"crossref","first-page":"e20220681","DOI":"10.1084\/jem.20220681","article-title":"Lysosomal cholesterol overload in macrophages promotes liver fibrosis in a mouse model of NASH","volume":"220","author":"Itoh","year":"2023","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib45","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.cmet.2025.01.020","article-title":"EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis","volume":"37","author":"Ma","year":"2025","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib46","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2020.03.010","article-title":"Cholesterol stabilizes TAZ in hepatocytes to promote experimental non-alcoholic steatohepatitis","volume":"31","author":"Wang","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib47","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1053\/j.gastro.2023.02.043","article-title":"A therapeutically targetable TAZ-TEAD2 pathway drives the growth of hepatocellular carcinoma via ANLN and KIF23","volume":"164","author":"Saito","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmet.2026.02.018_bib48","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib49","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1136\/gutjnl-2024-333074","article-title":"Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease","volume":"73","author":"Zhou","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.cmet.2026.02.018_bib50","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2796.2010.02305.x","article-title":"Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism","volume":"269","author":"Pramfalk","year":"2011","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib51","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clnu.2024.10.020","article-title":"The effect of lipid-lowering treatment on indices of MASLD in familial hypercholesterolemia patients","volume":"43","author":"Boutari","year":"2024","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.cmet.2026.02.018_bib52","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/01.RES.84.9.1085","article-title":"Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells","volume":"84","author":"Dichtl","year":"1999","journal-title":"Circ. Res."},{"key":"10.1016\/j.cmet.2026.02.018_bib53","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1053\/meta.2002.29963","article-title":"Linoleic acid-stimulated vascular adhesion molecule-1 expression in endothelial cells depends on nuclear factor-kappaB activation","volume":"51","author":"Dichtl","year":"2002","journal-title":"Metabolism"},{"key":"10.1016\/j.cmet.2026.02.018_bib54","doi-asserted-by":"crossref","first-page":"e143690","DOI":"10.1172\/JCI143690","article-title":"Lipid-induced endothelial vascular cell adhesion molecule 1 promotes nonalcoholic steatohepatitis pathogenesis","volume":"131","author":"Furuta","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cmet.2026.02.018_bib55","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/hep.28456","article-title":"Interleukin-1 and inflammasomes in alcoholic liver disease\/acute alcoholic hepatitis and nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"64","author":"Tilg","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib56","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.tem.2020.07.001","article-title":"Metabolism-associated molecular patterns (MAMPs)","volume":"31","author":"Wang","year":"2020","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib57","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/ni.2022","article-title":"Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling","volume":"12","author":"Wen","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cmet.2026.02.018_bib58","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.2279","article-title":"The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance","volume":"17","author":"Vandanmagsar","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib59","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1172\/JCI21047","article-title":"Splanchnic lipolysis in human obesity","volume":"113","author":"Nielsen","year":"2004","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cmet.2026.02.018_bib60","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jhep.2019.06.031","article-title":"Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease","volume":"71","author":"Rosso","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib61","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.cmet.2015.06.007","article-title":"Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis","volume":"22","author":"Xia","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib62","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1136\/gutjnl-2020-322509","article-title":"Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis","volume":"70","author":"Koh","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.cmet.2026.02.018_bib63","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/nm.4412","article-title":"Activation of intestinal hypoxia-inducible factor 2alpha during obesity contributes to hepatic steatosis","volume":"23","author":"Xie","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib64","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.cmet.2024.07.004","article-title":"A microbial metabolite inhibits the HIF-2alpha-ceramide pathway to mediate the beneficial effects of time-restricted feeding on MASH","volume":"36","author":"Zhang","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib65","doi-asserted-by":"crossref","first-page":"eaay8798","DOI":"10.1126\/scitranslmed.aay8798","article-title":"Targeting acid ceramidase inhibits YAP\/TAZ signaling to reduce fibrosis in mice","volume":"12","author":"Alsamman","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib66","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.cmet.2025.01.016","article-title":"Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism","volume":"37","author":"Jiang","year":"2025","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib67","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jhep.2016.01.002","article-title":"Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease","volume":"64","author":"Luukkonen","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib68","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cmet.2026.02.018_bib69","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/jhep.2003.50048","article-title":"Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease","volume":"37","author":"Li","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib70","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.cmet.2024.10.001","article-title":"Amino acid is a major carbon source for hepatic lipogenesis","volume":"36","author":"Liao","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib71","doi-asserted-by":"crossref","first-page":"eabg8117","DOI":"10.1126\/scitranslmed.abg8117","article-title":"Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib72","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.cmet.2023.10.008","article-title":"The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans","volume":"35","author":"Luukkonen","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib73","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jhep.2021.12.012","article-title":"Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease","volume":"76","author":"Govaere","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib74","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/hep.32112","article-title":"Hepatocyte-specific deletion of adipose triglyceride lipase (adipose triglyceride lipase\/patatin-like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice","volume":"75","author":"Fuchs","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib75","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/j.cmet.2024.08.012","article-title":"IL-22 resolves MASLD via enterocyte STAT3 restoration of diet-perturbed intestinal homeostasis","volume":"36","author":"Zhang","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib76","doi-asserted-by":"crossref","first-page":"682","DOI":"10.2337\/db23-0814","article-title":"Coagulation Factor VII fine-tunes hepatic steatosis by blocking AKT-CD36-mediated fatty acid uptake","volume":"73","author":"Zhang","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2026.02.018_bib77","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.cmet.2024.04.015","article-title":"A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARalpha and PCK1","volume":"36","author":"Gallage","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib78","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib79","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s42255-023-00801-2","article-title":"Itaconic acid underpins hepatocyte lipid metabolism in non-alcoholic fatty liver disease in male mice","volume":"5","author":"Weiss","year":"2023","journal-title":"Nat. Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib80","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-liver axis: Pathophysiological concepts and clinical implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib81","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib82","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1136\/gutjnl-2022-327365","article-title":"A mechanism by which gut microbiota elevates permeability and inflammation in obese\/diabetic mice and human gut","volume":"72","author":"Mishra","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.cmet.2026.02.018_bib83","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.cell.2024.03.034","article-title":"Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway","volume":"187","author":"Nie","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2026.02.018_bib84","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.cmet.2023.07.011","article-title":"Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis","volume":"35","author":"Kuang","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib85","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jhep.2024.09.032","article-title":"Bile acid metabolism and signalling in liver disease","volume":"82","author":"Fuchs","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib86","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.cell.2019.01.001","article-title":"Extensive unexplored human microbiome diversity revealed by over 150,000 genomes from metagenomes spanning age, geography, and lifestyle","volume":"176","author":"Pasolli","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2026.02.018_bib87","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib88","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41591-018-0061-3","article-title":"Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women","volume":"24","author":"Hoyles","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib89","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/HEP.0000000000000474","article-title":"An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations","volume":"78","author":"Carr","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib90","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40168-024-01990-y","article-title":"Discovery of robust and highly specific microbiome signatures of non-alcoholic fatty liver disease","volume":"13","author":"Nychas","year":"2025","journal-title":"Microbiome"},{"key":"10.1016\/j.cmet.2026.02.018_bib91","doi-asserted-by":"crossref","first-page":"108861","DOI":"10.1016\/j.isci.2024.108861","article-title":"Identification of commensal gut bacterial strains with lipogenic effects contributing to NAFLD in children","volume":"27","author":"Wei","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.cmet.2026.02.018_bib92","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/hep.30036","article-title":"Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease","volume":"69","author":"Ponziani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib93","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cmet.2020.06.005","article-title":"A universal gut-microbiome-derived signature predicts cirrhosis","volume":"32","author":"Oh","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib94","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1017\/S0007114514004127","article-title":"Dietary effects on human gut microbiome diversity","volume":"113","author":"Xu","year":"2015","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.cmet.2026.02.018_bib95","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.cmet.2023.08.002","article-title":"Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations","volume":"35","author":"Ni","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib96","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1136\/gutjnl-2019-318811","article-title":"Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease","volume":"69","author":"Sookoian","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.cmet.2026.02.018_bib97","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hep.31056","article-title":"Increased liver localization of lipopolysaccharides in human and experimental NAFLD","volume":"72","author":"Carpino","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib98","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/apt.14119","article-title":"Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease","volume":"46","author":"Pang","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.cmet.2026.02.018_bib99","doi-asserted-by":"crossref","first-page":"eabe6729","DOI":"10.1126\/science.abe6729","article-title":"Enterically derived high-density lipoprotein restrains liver injury through the portal vein","volume":"373","author":"Han","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.cmet.2026.02.018_bib100","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41586-024-07372-6","article-title":"Periportal macrophages protect against commensal-driven liver inflammation","volume":"629","author":"Miyamoto","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib101","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/hep.23122","article-title":"Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice","volume":"50","author":"Spruss","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib102","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10809","article-title":"Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity","volume":"482","author":"Henao-Mejia","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib103","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.cmet.2019.08.018","article-title":"Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae","volume":"30","author":"Yuan","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib104","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/s41591-022-02016-6","article-title":"Microbiome-derived ethanol in nonalcoholic fatty liver disease","volume":"28","author":"Meijnikman","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib105","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib106","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41575-025-01089-1","article-title":"Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma","volume":"22","author":"Lau","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib107","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/ni.3790","article-title":"A guiding map for inflammation","volume":"18","author":"Netea","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cmet.2026.02.018_bib108","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1053\/jhep.2001.29628","article-title":"Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients","volume":"34","author":"Crespo","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib109","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jhep.2011.01.048","article-title":"Lack of interleukin-1alpha or interleukin-1beta inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice","volume":"55","author":"Kamari","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib110","doi-asserted-by":"crossref","first-page":"840","DOI":"10.2119\/molmed.2010.00108","article-title":"Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss","volume":"17","author":"Moschen","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib111","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jhep.2011.04.007","article-title":"IL-1 cytokine family members and NAFLD: neglected in metabolic liver inflammation","volume":"55","author":"Tilg","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib112","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/liv.12537","article-title":"Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis","volume":"34","author":"Csak","year":"2014","journal-title":"Liver Int."},{"key":"10.1016\/j.cmet.2026.02.018_bib113","doi-asserted-by":"crossref","first-page":"24399","DOI":"10.1038\/srep24399","article-title":"A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet","volume":"6","author":"Yang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cmet.2026.02.018_bib114","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.cmet.2023.10.009","article-title":"The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease","volume":"35","author":"Sawada","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib115","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","article-title":"Hepatic inflammatory responses in liver fibrosis","volume":"20","author":"Hammerich","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib116","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41575-025-01045-z","article-title":"\u039cetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment","volume":"22","author":"Byrne","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib117","doi-asserted-by":"crossref","first-page":"e186424","DOI":"10.1172\/JCI186424","article-title":"Human genetics of metabolic dysfunction-associated steatotic liver disease: from variants to cause to precision treatment","volume":"135","author":"Chen","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cmet.2026.02.018_bib118","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41586-019-1797-8","article-title":"The integrative biology of type 2 diabetes","volume":"576","author":"Roden","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib119","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10875-011-9635-2","article-title":"The role of innate cells is coupled to a Th1-polarized immune response in pediatric nonalcoholic steatohepatitis","volume":"32","author":"Ferreyra Solari","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.cmet.2026.02.018_bib120","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4049\/jimmunol.1501175","article-title":"Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17\/resting regulatory T cell ratio in peripheral blood and in the liver","volume":"196","author":"Rau","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.cmet.2026.02.018_bib121","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/hep.26267","article-title":"Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice","volume":"58","author":"Henning","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib122","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/hep.23599","article-title":"Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease","volume":"51","author":"Syn","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib123","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-021-03233-8","article-title":"Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH","volume":"592","author":"Dudek","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib124","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature16969","article-title":"NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis","volume":"531","author":"Ma","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib125","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib126","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/HEP.0000000000000985","article-title":"Intestinal IL-33 promotes microbiota-derived trimethylamine N -oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1alpha","volume":"82","author":"Hai","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib127","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1038\/s41467-020-16274-w","article-title":"Sphingolipids produced by gut bacteria enter host metabolic pathways impacting ceramide levels","volume":"11","author":"Johnson","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cmet.2026.02.018_bib128","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.chom.2022.05.002","article-title":"Host hepatic metabolism is modulated by gut microbiota-derived sphingolipids","volume":"30","author":"Le","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cmet.2026.02.018_bib129","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cmet.2025.10.007","article-title":"Dietary fat disrupts a commensal-host lipid network that promotes metabolic health","volume":"38","author":"Klag","year":"2025","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib130","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41586-021-03832-5","article-title":"Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians","volume":"599","author":"Sato","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib131","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41586-022-04480-z","article-title":"Human gut bacteria produce T\u039717-modulating bile acid metabolites","volume":"603","author":"Paik","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib132","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.chom.2023.01.009","article-title":"Gut microbiome lipid metabolism and its impact on host physiology","volume":"31","author":"Brown","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cmet.2026.02.018_bib133","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41586-021-04083-0","article-title":"Host immunomodulatory lipids created by symbionts from dietary amino acids","volume":"600","author":"Oh","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib134","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41586-025-08990-4","article-title":"Targeting symbionts by apolipoprotein L proteins modulates gut immunity","volume":"643","author":"Yang","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib135","doi-asserted-by":"crossref","first-page":"108411","DOI":"10.1016\/j.pharmthera.2023.108411","article-title":"Lipid metabolism in Th17 cell function","volume":"245","author":"Kanno","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cmet.2026.02.018_bib136","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-024-03165-6","article-title":"Western diets and chronic diseases","volume":"30","author":"Adolph","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib137","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1053\/j.gastro.2014.12.036","article-title":"Food, immunity, and the microbiome","volume":"148","author":"Tilg","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmet.2026.02.018_bib138","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s43587-022-00286-w","article-title":"Long-term life history predicts current gut microbiome in a population-based cohort study","volume":"2","author":"Si","year":"2022","journal-title":"Nat Aging"},{"key":"10.1016\/j.cmet.2026.02.018_bib139","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1053\/j.gastro.2012.01.034","article-title":"A high-fat diet is associated with endotoxemia that originates from the gut","volume":"142","author":"Pendyala","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmet.2026.02.018_bib140","doi-asserted-by":"crossref","first-page":"G227","DOI":"10.1152\/ajpgi.00267.2012","article-title":"A novel mechanism for gut barrier dysfunction by dietary fat: epithelial disruption by hydrophobic bile acids","volume":"304","author":"Stenman","year":"2013","journal-title":"Am. J. Physiol., Gastrointest. Liver Physiol."},{"key":"10.1016\/j.cmet.2026.02.018_bib141","doi-asserted-by":"crossref","first-page":"19835","DOI":"10.1038\/s41598-024-70931-4","article-title":"Sex-dependent effects of a high fat diet on metabolic disorders, intestinal barrier function and gut microbiota in mouse","volume":"14","author":"Lefebvre","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cmet.2026.02.018_bib142","doi-asserted-by":"crossref","first-page":"28990","DOI":"10.1038\/srep28990","article-title":"High fat diets induce colonic epithelial cell stress and inflammation that is reversed by IL-22","volume":"6","author":"Gulhane","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cmet.2026.02.018_bib143","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature11225","article-title":"Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-\/- mice","volume":"487","author":"Devkota","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib144","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1016\/j.cell.2022.08.005","article-title":"Microbiota imbalance induced by dietary sugar disrupts immune-mediated protection from metabolic syndrome","volume":"185","author":"Kawano","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2026.02.018_bib145","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.cmet.2021.09.004","article-title":"\u201cSweet death\u201d: Fructose as a metabolic toxin that targets the gut-liver axis","volume":"33","author":"Febbraio","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib146","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s42255-020-0261-2","article-title":"Fructose stimulated de novo lipogenesis is promoted by inflammation","volume":"2","author":"Todoric","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib147","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.nutres.2021.04.008","article-title":"A rise in Proteobacteria is an indicator of gut-liver axis-mediated nonalcoholic fatty liver disease in high-fructose-fed adult mice","volume":"91","author":"Vasques-Monteiro","year":"2021","journal-title":"Nutr. Res."},{"key":"10.1016\/j.cmet.2026.02.018_bib148","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-020-2101-7","article-title":"Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate","volume":"579","author":"Zhao","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib149","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.cmet.2022.08.005","article-title":"PIDDosome-SCAP crosstalk controls high-fructose-diet-dependent transition from simple steatosis to steatohepatitis","volume":"34","author":"Kim","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib150","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41586-024-08317-9","article-title":"FBP1 controls liver cancer evolution from senescent MASH hepatocytes","volume":"637","author":"Gu","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib151","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature09922","article-title":"Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease","volume":"472","author":"Wang","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib152","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cell.2016.02.011","article-title":"Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk","volume":"165","author":"Zhu","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2026.02.018_bib153","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1093\/eurheartj\/ehx342","article-title":"Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis","volume":"38","author":"Schiattarella","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cmet.2026.02.018_bib154","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1017\/S0007114524000631","article-title":"Trimethylamine N-oxide, choline and its metabolites are associated with the risk of non-alcoholic fatty liver disease","volume":"131","author":"Ma","year":"2024","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.cmet.2026.02.018_bib155","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cell.2018.09.055","article-title":"Microbially produced imidazole propionate impairs insulin signaling through mTORC1","volume":"175","author":"Koh","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2026.02.018_bib156","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41586-025-09263-w","article-title":"Imidazole propionate is a driver and therapeutic target in atherosclerosis","volume":"645","author":"Mastrangelo","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib157","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/hep.30583","article-title":"PNPLA3, CGI-58, and inhibition of hepatic triglyceride hydrolysis in mice","volume":"69","author":"Wang","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib158","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.molmet.2019.01.013","article-title":"Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice","volume":"22","author":"Lind\u00e9n","year":"2019","journal-title":"Mol. Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib159","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2024.12.046","article-title":"AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials","volume":"83","author":"Armisen","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib160","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1056\/NEJMc2402341","article-title":"Phase 1 trials of PNPLA3 siRNA in I148M homozygous patients with MAFLD","volume":"391","author":"Fabbrini","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib161","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.27490","article-title":"Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease","volume":"61","author":"Dongiovanni","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib162","doi-asserted-by":"crossref","first-page":"11585","DOI":"10.1038\/s41598-019-47737-w","article-title":"The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids","volume":"9","author":"Prill","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cmet.2026.02.018_bib163","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008955","article-title":"Disruption of the ERLIN-TM6SF2-APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease","volume":"16","author":"Li","year":"2020","journal-title":"PLOS Genet."},{"key":"10.1016\/j.cmet.2026.02.018_bib164","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/gutjnl-2020-320646","article-title":"LPIAT1\/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover","volume":"70","author":"Tanaka","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.cmet.2026.02.018_bib165","doi-asserted-by":"crossref","first-page":"7430","DOI":"10.1038\/s41467-022-35158-9","article-title":"A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes","volume":"13","author":"Alharthi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cmet.2026.02.018_bib166","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/liv.15857","article-title":"Mitochondrial amidoxime-reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome","volume":"44","author":"Dutta","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.cmet.2026.02.018_bib167","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3350\/cmh.2024.0642","article-title":"Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation","volume":"31","author":"Ciociola","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib168","doi-asserted-by":"crossref","first-page":"e132158","DOI":"10.1172\/jci.insight.132158","article-title":"Hydroxysteroid 17-\u03b2 dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease","volume":"5","author":"Luukkonen","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.cmet.2026.02.018_bib169","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/j.cgh.2022.11.002","article-title":"The protection conferred by HSD17B13 rs72613567 on hepatic fibrosis is likely mediated by lowering ballooning and portal inflammation","volume":"21","author":"Vilar-Gomez","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib170","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2022.11.025","article-title":"A phase I\/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis","volume":"78","author":"Mak","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib171","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jhep.2022.03.031","article-title":"Rare ATG7 genetic variants predispose to severe fatty liver disease","volume":"77","author":"Baselli","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib172","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/jcb.27378","article-title":"PNPLA3 variant M148 causes resistance to starvation-mediated lipid droplet autophagy in human hepatocytes","volume":"120","author":"Negoita","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.cmet.2026.02.018_bib173","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3803\/EnM.2024.2068","article-title":"Thyroid hormone-mediated selective autophagy and its implications in countering metabolic dysfunction-associated steatotic liver disease","volume":"39","author":"Sinha","year":"2024","journal-title":"Endocrinol. Metab. (Seoul)"},{"key":"10.1016\/j.cmet.2026.02.018_bib174","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib175","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41586-021-03974-6","article-title":"Convergent somatic mutations in metabolism genes in chronic liver disease","volume":"598","author":"Ng","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib176","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.cell.2023.03.014","article-title":"Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2026.02.018_bib177","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1053\/j.gastro.2019.12.054","article-title":"Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in nonalcoholic fatty liver disease","volume":"158","author":"Azzu","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmet.2026.02.018_bib178","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1126\/science.7678183","article-title":"Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance","volume":"259","author":"Hotamisligil","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.cmet.2026.02.018_bib179","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41577-024-01103-8","article-title":"Adipokines: masterminds of metabolic inflammation","volume":"25","author":"Tilg","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cmet.2026.02.018_bib180","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1172\/JCI117899","article-title":"The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase","volume":"95","author":"Kern","year":"1995","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cmet.2026.02.018_bib181","first-page":"847","article-title":"Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid","volume":"83","author":"Fried","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib182","first-page":"4196","article-title":"Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo","volume":"82","author":"Mohamed-Ali","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib183","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/hep.22350","article-title":"Visceral fat: a key mediator of steatohepatitis in metabolic liver disease","volume":"48","author":"van der Poorten","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib184","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/gut.2010.214577","article-title":"Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression","volume":"59","author":"Moschen","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.cmet.2026.02.018_bib185","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.ATV.0000073313.16135.21","article-title":"Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients","volume":"23","author":"Kopp","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cmet.2026.02.018_bib186","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/en.2003-1336","article-title":"Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans","volume":"145","author":"Fain","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.cmet.2026.02.018_bib187","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1126\/science.1160794","article-title":"A stress signaling pathway in adipose tissue regulates hepatic insulin resistance","volume":"322","author":"Sabio","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.cmet.2026.02.018_bib188","doi-asserted-by":"crossref","first-page":"G385","DOI":"10.1152\/ajpgi.00104.2023","article-title":"Inhibition of visceral adipose tissue-derived pathogenic signals by activation of adenosine A(2A)R improves hepatic and cardiac dysfunction of NASH mice","volume":"326","author":"Huang","year":"2024","journal-title":"Am. J. Physiol., Gastrointest. Liver Physiol."},{"key":"10.1016\/j.cmet.2026.02.018_bib189","doi-asserted-by":"crossref","first-page":"115251","DOI":"10.1016\/j.celrep.2025.115251","article-title":"Exercise-induced adipokine Nrg4 alleviates MASLD by disrupting hepatic cGAS-STING signaling","volume":"44","author":"Chen","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.cmet.2026.02.018_bib190","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1053\/j.gastro.2025.03.033","article-title":"MASH adipose tissue macrophages secrete extracellular vesicles that activate liver fibrosis in obese male mice","volume":"169","author":"Rohm","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmet.2026.02.018_bib191","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2015.05.044","article-title":"Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease","volume":"149","author":"du Plessis","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmet.2026.02.018_bib192","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2022.10.027","article-title":"Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis","volume":"78","author":"Shen","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib193","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2023.10.039","article-title":"Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH","volume":"80","author":"Boesch","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib194","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance","volume":"79","author":"Hutchison","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib195","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmet.2026.02.018_bib196","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib197","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jhep.2024.10.044","article-title":"Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease","volume":"82","author":"Kim","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib198","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1053\/j.gastro.2012.05.049","article-title":"Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice","volume":"143","author":"Meng","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmet.2026.02.018_bib199","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/hep.26592","article-title":"NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice","volume":"59","author":"Wree","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib200","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib201","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jcmgh.2022.06.007","article-title":"Cell-specific deletion of NLRP3 inflammasome identifies myeloid cells as key drivers of liver inflammation and fibrosis in murine steatohepatitis","volume":"14","author":"Kaufmann","year":"2022","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib202","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41467-020-20303-z","article-title":"Hepatocyte-specific IL11 cis-signaling drives lipotoxicity and underlies the transition from NAFLD to NASH","volume":"12","author":"Dong","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cmet.2026.02.018_bib203","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-024-07701-9","article-title":"Inhibition of IL-11 signalling extends mammalian healthspan and lifespan","volume":"632","author":"Widjaja","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib204","doi-asserted-by":"crossref","first-page":"156004","DOI":"10.1016\/j.metabol.2024.156004","article-title":"Metabolic dysfunction-associated steatotic liver disease and its link to cancer","volume":"160","author":"Kalligeros","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.cmet.2026.02.018_bib205","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4093\/dmj.2023.0240","article-title":"Hepatic fibrosis and cancer: the silent threats of metabolic syndrome","volume":"48","author":"Friedman","year":"2024","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.cmet.2026.02.018_bib206","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ijc.35097","article-title":"Metabolic dysfunction-associated steatotic liver disease has become the most common cause of hepatocellular carcinoma in Sweden: A nationwide cohort study","volume":"156","author":"Vaz","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.cmet.2026.02.018_bib207","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cell.2009.12.052","article-title":"Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression","volume":"140","author":"Park","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2026.02.018_bib208","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.cell.2018.09.053","article-title":"Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC","volume":"175","author":"Grohmann","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2026.02.018_bib209","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cell.2013.09.031","article-title":"Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling","volume":"155","author":"He","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2026.02.018_bib210","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature21363","article-title":"Inflammation, metaflammation and immunometabolic disorders","volume":"542","author":"Hotamisligil","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib211","doi-asserted-by":"crossref","first-page":"1012887","DOI":"10.3389\/fphys.2022.1012887","article-title":"Serum high-sensitive C-reactive protein is a simple indicator for all-cause among individuals with MAFLD","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.cmet.2026.02.018_bib212","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib213","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.cmet.2024.04.020","article-title":"Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periosti","volume":"36","author":"Xie","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib214","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.124.070535","article-title":"Cardiovascular-liver-metabolic health: recommendations in screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease in cardiovascular disease via modified Delphi approach","volume":"151","author":"Chew","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.cmet.2026.02.018_bib215","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S2468-1253(24)00310-8","article-title":"Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease","volume":"10","author":"Gries","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib216","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2026.02.018_bib217","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2026.02.018_bib218","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa2002449","article-title":"Life expectancy after bariatric surgery in the Swedish Obese Subjects Study","volume":"383","author":"Carlsson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib219","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/SLA.0000000000006003","article-title":"Decreased risk of esophageal adenocarcinoma after gastric bypass surgery in a cohort study from 3 Nordic countries","volume":"278","author":"Hardvik \u00c5kerstr\u00f6m","year":"2023","journal-title":"Ann. Surg."},{"key":"10.1016\/j.cmet.2026.02.018_bib220","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.cmet.2026.02.018_bib221","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.cgh.2023.09.018","article-title":"Longitudinal outcomes associated with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of 129 studies","volume":"22","author":"Chan","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib222","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2019.08.018","article-title":"The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study","volume":"71","author":"Allen","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib223","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/gutjnl-2024-333087","article-title":"Unravelling the obesity paradox in MASLD patients with extrahepatic cancer","volume":"74","author":"Li","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.cmet.2026.02.018_bib224","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2026.02.018_bib225","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","article-title":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH","volume":"79","author":"Tacke","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib226","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.cmet.2024.03.011","article-title":"New and emerging treatments for metabolic dysfunction-associated steatohepatitis","volume":"36","author":"Tincopa","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib227","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/HEP.0000000000001254","article-title":"Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis","volume":"82","author":"Souza","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2026.02.018_bib228","doi-asserted-by":"crossref","first-page":"e186425","DOI":"10.1172\/JCI186425","article-title":"Therapeutic horizons in metabolic dysfunction-associated steatohepatitis","volume":"135","author":"Newsome","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cmet.2026.02.018_bib229","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib230","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s00018-024-05507-6","article-title":"GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells","volume":"81","author":"da Silva Lima","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.cmet.2026.02.018_bib231","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1111\/apt.70196","article-title":"Review article: GLP-1 receptor agonists and glucagon\/GIP\/GLP-1 receptor dual or triple agonists-mechanism of action and emerging therapeutic landscape in MASLD","volume":"61","author":"Zafer","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.cmet.2026.02.018_bib232","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib233","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib234","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib235","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib236","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib237","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cmet.2019.01.004","article-title":"A dozen years of discovery: insights into the physiology and pharmacology of FGF21","volume":"29","author":"Kliewer","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib238","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cmet.2025.04.014","article-title":"FGF21 reverses MASH through coordinated actions on the CNS and liver","volume":"37","author":"Rose","year":"2025","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib239","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cmet.2023.02.005","article-title":"FGF21 counteracts alcohol intoxication by activating the noradrenergic nervous system","volume":"35","author":"Choi","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib240","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cmet.2021.12.024","article-title":"FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit","volume":"34","author":"Flippo","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib241","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib242","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in compensated liver cirrhosis caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib243","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib244","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S2468-1253(25)00067-6","article-title":"Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial","volume":"10","author":"Loomba","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib245","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.3390\/ijms24065843","article-title":"Resmetirom ameliorates NASH-model mice by suppressing STAT3 and NF-\u03baB signaling pathways in an RGS5-dependent manner","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cmet.2026.02.018_bib246","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2026.02.018_bib247","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/gutjnl-2023-330596","article-title":"Thyroid hormone receptor-beta agonists: new MASLD therapies on the horizon","volume":"73","author":"Byrne","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.cmet.2026.02.018_bib248","doi-asserted-by":"crossref","first-page":"e194751","DOI":"10.1172\/JCI194751","article-title":"Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits","volume":"135","author":"Wong","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cmet.2026.02.018_bib249","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41575-025-01096-2","article-title":"Lessons from incretin-based therapy in MASH and obesity","volume":"22","author":"Tilg","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib250","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-\/-) and LDLr(-\/-) mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.cmet.2026.02.018_bib251","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1139\/cjpp-2025-0148","article-title":"Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective","volume":"103","author":"Ros-Madrid","year":"2025","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.cmet.2026.02.018_bib252","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1196\/annals.1447.049","article-title":"Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency","volume":"1150","author":"Xue","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.cmet.2026.02.018_bib253","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.bbrc.2009.10.015","article-title":"Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression","volume":"390","author":"le Kim Chung","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cmet.2026.02.018_bib254","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbrc.2012.07.086","article-title":"Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation","volume":"425","author":"Shiraishi","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cmet.2026.02.018_bib255","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib256","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097554","article-title":"Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism","volume":"9","author":"Krasner","year":"2014","journal-title":"PLOS One"},{"key":"10.1016\/j.cmet.2026.02.018_bib257","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/cbf.3751","article-title":"Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice","volume":"40","author":"Martins","year":"2022","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.cmet.2026.02.018_bib258","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1038\/s41591-025-03799-0","article-title":"Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Jara","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib259","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/s41423-025-01307-5","article-title":"Immunopathogenic mechanisms and immunoregulatory therapies in MASLD","volume":"22","author":"He","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.cmet.2026.02.018_bib260","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages\u2606","volume":"73","author":"Lefere","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib261","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/s41467-024-47919-9","article-title":"The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis","volume":"15","author":"Cooreman","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cmet.2026.02.018_bib262","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13861","article-title":"Treating metabolic dysfunction-associated steatohepatitis: The fat-trimming FGF21 approach","volume":"26","author":"Li","year":"2025","journal-title":"Obes. Rev."},{"key":"10.1016\/j.cmet.2026.02.018_bib263","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.intimp.2015.01.005","article-title":"Fibroblast growth factor 21 (FGF21) ameliorates collagen-induced arthritis through modulating oxidative stress and suppressing nuclear factor-kappa B pathway","volume":"25","author":"Yu","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cmet.2026.02.018_bib264","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202401397R","article-title":"Therapeutic effects of FGF21 mimetic bFKB1 on MASH and atherosclerosis in Ldlr-\/-.Leiden mice","volume":"38","author":"Inia","year":"2024","journal-title":"FASEB J."},{"key":"10.1016\/j.cmet.2026.02.018_bib265","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70016","article-title":"FGF21 analogues in patients with metabolic diseases: systematic review and meta-analysis of randomised controlled trials","volume":"45","author":"Theofilis","year":"2025","journal-title":"Liver Int."},{"key":"10.1016\/j.cmet.2026.02.018_bib266","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s42255-024-01043-6","article-title":"An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"6","author":"Vacca","year":"2024","journal-title":"Nat. Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib267","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s42255-024-00985-1","article-title":"From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research","volume":"6","author":"Hsu","year":"2024","journal-title":"Nat. Metab."},{"key":"10.1016\/j.cmet.2026.02.018_bib268","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1038\/s41591-024-03284-0","article-title":"Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Jamialahmadi","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2026.02.018_bib269","doi-asserted-by":"crossref","first-page":"e186421","DOI":"10.1172\/JCI186421","article-title":"Dissecting the mechanisms of MASLD fibrosis in the era of single-cell and spatial omics","volume":"135","author":"Colella","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cmet.2026.02.018_bib270","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/s41588-025-02237-8","article-title":"Single-cell eQTL analysis identifies genetic variation underlying metabolic dysfunction-associated steatohepatitis","volume":"57","author":"Hong","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cmet.2026.02.018_bib271","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/s41590-025-02255-y","article-title":"Single-cell atlas of human liver and blood immune cells across fatty liver disease stages reveals distinct signatures linked to liver dysfunction and fibrogenesis","volume":"26","author":"Martin","year":"2025","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cmet.2026.02.018_bib272","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jhep.2024.08.008","article-title":"Thyroid hormone receptor-beta agonist HSK31679 alleviates MASLD by modulating gut microbial sphingolipids","volume":"82","author":"Zhang","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cmet.2026.02.018_bib273","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2024-334023","article-title":"Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists","volume":"74","author":"Targher","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.cmet.2026.02.018_bib274","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nri3041","article-title":"The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease","volume":"11","author":"Gleeson","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cmet.2026.02.018_bib275","doi-asserted-by":"crossref","first-page":"101421","DOI":"10.1016\/j.jhepr.2025.101421","article-title":"Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease","volume":"7","author":"Schwabe","year":"2025","journal-title":"JHEP Rep."}],"container-title":["Cell Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1550413126000872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1550413126000872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T12:26:18Z","timestamp":1785932778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1550413126000872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":275,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1550413126000872"],"URL":"https:\/\/doi.org\/10.1016\/j.cmet.2026.02.018","relation":{},"ISSN":["1550-4131"],"issn-type":[{"value":"1550-4131","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The many pathways driving liver inflammation in MASH","name":"articletitle","label":"Article Title"},{"value":"Cell Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmet.2026.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}